Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
President Trump announces multiple judicial nominees, accuses court...
Top House committees accuse Dem fundraising giant of...
Trump to rename Persian Gulf the Arabian Gulf...
‘New sheriff in town’: State finance leader rallies...
Trump announces MAHA advocate Casey Means will be...
Trump offers to help India, Pakistan amid growing...
Lone Republican becomes only lawmaker to vote against...
Trump halts military strikes on Houthis but expert...
Retired judges criticize Trump admin over arrest of...
REAL ID deadline comes and goes – airports...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

by admin August 14, 2024
August 14, 2024
Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Highlights:

Analysis of 400 patients in Phase 2 SAMDE study for current Major Depressive Episode (cMDE) study utilising MEB-001MEB-001 is TrivarX’s proprietary AI-driven algorithm which can assist with the effective screening of a cMDEMEB-001 performance results from Phase 2 SAMDE study reported high performance, marking a significant achievement in the Company:Sensitivity: 87% (95% CI 73-95%)Specificity: 72% (95% CI 66-77%)Positive Predictive Value: 35% (95% CI 27-45%)Negative Predictive Value: 97% (95% CI 93-99%)Results provide strong validation of MEB-001’s ability to assist in the screening and diagnosis of a cMDE – a condition which is commonly misdiagnosedThere is currently no screening undertaken for cMDE in sleep centres in the US or globally, representing a major commercial opportunity for TrivarXResults advance TRI’s aim to become the first depression screening tool used in clinical practice in sleep centres

There is a well-established connection between mental health conditions, such as depression, and sleep disturbances. People with insomnia may have a tenfold higher risk of developing cMDE and among people with depression, 75% of sufferers have trouble falling or staying asleepi. Furthermore, misdiagnosis of major depressive disorder is estimated at upwards of 65% in the USii. Despite this, depression screening is not routinely included in sleep studies, even though up to 21% of people undergoing a sleep study have depressioniii.

Positive results from SAMDE study highlight MEB-001’s significant potential:

The objective of the study (ClinicalTrials.gov ID NCT05708222) was to use MEB-001 to detect the likelihood of a cMDE using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep clinic. A total of 400 patients were recruited across 15 sleep centres in the US. Out of these, 73 patients were excluded due to incomplete data or a split night/titration sleep study. MEB-001 also automatically identified 32 patients with significant anomalies in their sleep data. Notably, the MEB-001 algorithm was locked prior to the analysis ensuring no data from Phase 2 was used in its training.

Analysis of the results showed that MEB-001 reported promising performance across key parameters including sensitivity of 87% (95% CI 73-96%), specificity of 72% (95% CI 66-77%), positive predictive value (PPV) of 35% (95% CI 27-45%) and negative predictive value (NPV) of 97% (95% CI 93-99%) (refer table below).

These results provide considerable validation of MEB-001 and its ability in the screening and diagnosis of a current Major Depressive Episode (cMDE) in test subjects.

Management commentary:

Non-executive Chairman, David Trimboli said: “We are very excited to share the results from our Phase2 study, which highlight the effectiveness of MEB-001 in screening for cMDE. This is underscored by the significant increase in sensitivity coming from recent improvements to the underlying algorithm, which was increased from 71% in Phase 1, to 87% in Phase 2 – demonstrating that the algorithm can successfully identify more people with cMDE. Our very high NPV validates MEB-001’s potential as a screening test, with the likelihood of having depression when testing negative to be less than 3%.

“There is currently no screening undertaken for cMDE in sleep centres in the US or globally. Our most recent results reaffirm the potential of MEB-001 to become the first depression screening tool used in clinical practice in sleep centres and marks a significant achievement in the Company’s history.”

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
WGC: Gold ETFs Notch Best Performance Since April 2022
next post
American Rare Earths Forges a New Path to Accelerate Development of Key Wyoming Asset

You may also like

Heritage Receives Drill Permitand Secures additional Drill Program...

January 27, 2025

AMD to Acquire ZT Systems for US$4.9 Billion...

August 20, 2024

Top 5 Canadian Mining Stocks This Week: Wealth...

January 26, 2025

Significant Exploration Target for Golden Ridge, NE Tasmania

November 12, 2024

WESTERN COPPER AND GOLD STRENGTHENS MANAGEMENT TEAM

July 22, 2024

Top 7 Global Lithium Stocks in 2025

April 4, 2025

Bold Ventures Adds to Management Team

August 8, 2024

Further High-Grade Intercepts at Kamperman

March 24, 2025

Space Mining Startup AstroForge Sets Sights on Off-Earth...

August 23, 2024

5 Best-performing Canadian Pharma Stocks of 2025

January 11, 2025

Recent Posts

  • President Trump announces multiple judicial nominees, accuses court system of blocking him from doing his job
  • Top House committees accuse Dem fundraising giant of facilitating ‘bad actors’ in bombshell DOJ letter
  • Trump to rename Persian Gulf the Arabian Gulf ahead of US-Iran nuclear talks, Middle East trip: report
  • ‘New sheriff in town’: State finance leader rallies around key Trump victory saving ‘taxpayer dollars’
  • Trump announces MAHA advocate Casey Means will be new surgeon general nominee

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (710)
    • Investing (2,051)
    • Politics (2,543)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.